A
Aquestive Therapeutics, Inc. (AQST)
NGM – Real vaqt narxi. Valyuta: USD
4.16
-0.18 (-4.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.16
-0.18 (-4.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aquestive Therapeutics, Inc. Amerika Qo'shma Shtatlari va xalqaro miqyosda farmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniya tutqanoqlarni davolash uchun diazepamning bukka (yonoq ichiga) yuboriladigan eriydigan plyonkasi bo'lgan Libervantni; opiatga qaramlikni davolash uchun buprenorfin va naloksonning til ostiga qo'yiladigan plyonkali shakli bo'lgan Suboxone'ni; riluzolning og'iz orqali yuboriladigan plyonkali shakli bo'lgan EMYLIF'ni; ondansetronning og'iz orqali yuboriladigan eriydigan plyonkali shakli bo'lgan ONDIF'ni; epilepsiyaning noyob, davolash qiyin bo'lgan shakli bilan bog'liq tutqanoqlarni davolash uchun ishlatiladigan klobazamning og'iz orqali yuboriladigan eriydigan plyonkali shakli bo'lgan SYMPAZAN'ni; apomorfinning til ostiga qo'yiladigan plyonkali shakli bo'lgan KYNMOBI'ni; hamda 6 yosh va undan katta bemorlarda ADHDni davolash uchun kuniga bir marta FDA tomonidan tasdiqlangan AZSTARYS'ni taklif etadi. Kompaniyaning o'ziga xos rivojlanayotgan mahsulotlari orasida anafilaksiya, shu jumladan allergik reaktsiyalarni shoshilinch davolash uchun 3-bosqichli klinik sinovdan o'tayotgan epinefrinni o'z ichiga olgan til ostiga qo'yiladigan plyonkasi bo'lgan Anaphylm; hamda alopesiya areatani davolash uchun 2-bosqichli klinik sinovdan o'tayotgan topik geli bo'lgan AQST-108 mavjud. Bundan tashqari, kompaniya markaziy asab tizimining ba'zi kasalliklaridan aziyat chekayotgan bemorlar uchun PharmFilm texnologiyasini; hamda epinefrin prodrug platformasi bo'lgan Adrenaverse'ni ishlab chiqadi. Kompaniya 2004-yilda tashkil etilgan bo'lib, shtab-kvartirasi Nyu-Jersi shtatining Uorren shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Matthew Greenhawt B.Sc., M.B.A., M.D. | Chief Medical Officer |
| Dr. Matthew William Davis M.D., R.Ph. | Chief Development Officer |
| Dr. Melina T. Cioffi Pharm.D. | Senior Vice President of Regulatory Affairs |
| Mr. A. Ernest Toth Jr. | Senior VP & CFO |
| Mr. Daniel Barber | CEO, President & Director |
| Mr. Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer |
| Mr. Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer |
| Ms. Cassie Jung | Chief Operating Officer |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Corporate Secretary |
| Ms. Sherry Korczynski | Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-24 | DEFA14A | ny20064249x2_defa14a.htm |
| 2026-04-24 | DEF 14A | ny20064249x1_def14a.htm |
| 2026-03-30 | 8-K | aqst-20260330.htm |
| 2026-03-20 | 8-K | aqst-20260316.htm |
| 2026-03-04 | 8-K | aqst-20260303.htm |
| 2026-02-26 | 8-K | aqst-20260226.htm |
| 2026-02-02 | 8-K | aqst-20260130.htm |
| 2026-01-21 | S-8 | o116265s8.htm |
| 2026-01-09 | 8-K | aqst-20260109.htm |
| 2025-11-06 | 8-K | aqst-20251106.htm |